Conference Website & Partnering Platform 

Programme

Programme

The EBDC 2015 will examine topics such as next generation medicines for autoimmune diseases. We will also look at companion diagnostics and other key market drivers in oncology, discuss alternatives for biotech financing and will evaluate if the hype on immunotherapies can realize its promise.

Learn more

Partnering

Partnering

Following the successful premiere in 2014 (with an uptake of 53% of the attendees), conference partnering will be offered again this year, allowing you to meet privately with international decision makers from the biotech and pharmaceutical sectors, as well as other life sciences industry suppliers.

Learn more

Exhibition

Exhibition

Reliable partners in conducting clinical trials are the key to a drug’s successful benefit assessment, both for innovative biotech companies and global pharmaceutical companies. Both small and large CROs will be able to present their expertise at the exhibition.

Learn more

Event Profile

The EBDC is an annual event that brings leading decision makers from international pharmaceutical companies and European biotech firms together with representatives of private equity and venture capital companies (see list of attending companies). The EBDC provides a forum for making contacts and discussing topics and trends of relevance to the market. The conference is attended by CEOs, managing directors and senior business development managers.

About half of innovative drugs result from national – but especially international – collaborations. This is why the motto for this years' event is:

Transborder > Transaction > Translation

Attending Companies

Representatives of the following companies have already confirmed their attendance (you must be logged in to see the company’s attendees):

2 Bridge, 3P Biopharmaceuticals, Abbvie, Ablynx, acromion, AiCuris, Alacris Theranostics, amcure, Amgen, Anacura, Ascenion, Astra Zeneca, AYOXXA, Bayer, BCNP Consultants, Berlin Partner for Business and Technology, Bibitec, BIO.be, Biocrates, Biogazelle, BioKryo, BioMed X, BioReg Consultancy, Bioskills, Biotechgate, Biotechsubsidy, Biotype Diagnostics, Boehringer Ingelheim Venture Fund, CD3 (KULeuven), Cell Therapy, Certara, Ci3 Cluster Management, City of Ghent, CHHC, CPS Cortex, Cresco Business Law Firm, Curevac, Domain Associates, EuropaBio, FGK Clinical Research, FlandersBio, Flanders Investment and Trade, Forbion, Galapagos, Ghent University, Gimv, HALIX, Heraeus, Inovigate, Janssen Cilag, Janssen Pharmaceutica, Janssen Research & Development, Johnson & Johnson Innovation, KBC, Kinesis Pharma, Lead Discovery Center, Lipotype, LSI Sachsen, Medigene, Merck Serono, Merck Serono Venture Fund, microDimensions, MLM Medical Labs, Mologen, MSD, Napp Pharmaceuticals, Nordmark Pharma, oncgnostics, OVIZIO Imaging Systems, Pharmavize, Pharma Lex, Phenex Pharmaceuticals, Pfizer, Polyphor, Probiodrug, PwC, Quintiles, ReGenesis, reMYND, Roche Diagnostics, Sacura, Sanofi, Selvita, SMS Oncology, Targos Molecular Pathology, Taros Chemicals, Teva Pharmaceuticals, Technologiepark Heidelberg, Therasolve/a>, Turnstone Communications, UCB Pharma, VWR International, Xendo, ZPZ Patentanwälte